Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
University of California San Diego · Liverpool John Moores University · +31 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
50
total citations
- FWCI
- 75.53
- Percentile
- 100%
- References
- 14
Citations per year
Authors
27- RNRamez N. EskanderCorresponding
University of California San Diego, Liverpool John Moores University
- MWMichael W. Sill
Roswell Park Comprehensive Cancer Center
- LBLindsey Beffa
Cleveland Clinic, Cleveland Foundation
- RGRichard G. Moore
University of Rochester Medical Center
- JMJoanie Mayer Hope
Alaska Women's Cancer Care
Topics & keywords
Topics
Keywords
- Pembrolizumab
- Oncology
- Endometrial cancer
- Medicine
- Internal medicine
- Randomized controlled trial
- Chemotherapy
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.